Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abp688
- Development stage
- Phase 1
- Lead developer
- Novartis
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
ABP688 is a highly selective and noncompetitive antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5). It is primarily used as a radiolabeled positron emission tomography (PET) ligand—most commonly in its carbon-11 labeled form ([11C]ABP688)—to quantify mGluR5 receptor availability in the brain. ABP688 readily crosses the blood-brain barrier and binds specifically to mGluR5-rich regions. It has been utilized in clinical research to investigate neurological and psychiatric conditions such as Alzheimer's disease, major depressive disorder, chronic neuropathic pain, anxiety disorders, epilepsy, and for studying glutamatergic network alterations during epileptogenesis[1][2][3][4][7][8]. The compound was originally developed by Novartis.
- Other names
- 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone-O-methyl-oxime
02
Targets
GRM5 (Metabotropic glutamate receptor 5)
Beyond the preview
Go deeper on abp688.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abp688.